Brief: CLS Granted Patent In China For Product And Method Of Controlling Treatment With imILT Protocol
23/03/2022 11:03
March 23 (Reuters) - Clinical Laserthermia Systems AB
CLSRb.ST :
* CLS GRANTED PATENT IN CHINA FOR THE PRODUCT AND METHOD OF
CONTROLLING TREATMENT WITH IMILT PROTOCOL
* CHINESE PATENT IS VALID UNTIL 2034 AND PROTECTS CLS
TECHNOLOGY
FOR CONTROLLING HEAT TREATMENT ACCORDING TO CLS IMILT PROTOCOL
Source text for Eikon: ID:nWkrbx60Jz
Further company coverage: CLSRb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Clinical Laserthermia Systems AB
See all newsBrief: CLS Enters Research Agreement With U.S. National Cancer Institute
Sweden's CLS Q1 sales fall 72% after partner talks
Brief: Clinical Laserthermia Systems Q1 EBIT Sek 1.7 Mln
Brief: CLS Receives Order Worth SEK 23 Mln For Prism Business
Brief: CLS Expects To Achieve Positive Cash Flow From Q4 2026 To Q1 2028